not saying that it does not work, in fact for some patients it is simply fantastic, but still...they have damaged their reputation with patients
nature.com/articles/s44276-...
The PSMAfore and VISION trials for Lutetium-177 PSMA-617 in prostate cancer exhibit design flaws that bias outcomes toward the experimental arm. Issues include reliance on surrogate endpoints like rPFS, suboptimal control treatments that do not reflect current standards, inappropriate cross-over from control to experimental treatment, and high rates of informative censoring. These flaws can mislead regulatory approvals and result in unproven, costly treatments being adopted, misaligning clinical trials with genuine patient benefits and potentially leading to significant, unwarranted healthcare spending.